Sotera Health CoSHC
▲ PositiveCapitalrelevance
Raises 2026 outlook after strong Q2 with revenue and EBITDA growth.
Impact on stocks 1
Biotech & Genomic Medicine
Sotera Health CoSotera Health raised its full-year 2026 outlook after reporting second-quarter revenue of $321 million, up 9.2% year over year, or 8% on a constant currency basis. Adjusted EBITDA grew 10% to $166 million, with margins expanding 36 basis points to 51.6%, and adjusted EPS rose 30% to $0.26 per diluted share. The company now expects constant currency revenue growth of 5.25% to 6.75% and adjusted EBITDA growth of 5.75% to 7.25% for 2026, up from prior guidance. Segment performance was broad-based, with Sterigenics delivering 7% constant currency revenue growth, Nordion up 16.7%, and Nelson Labs up 5.4%. CEO Alton Shader, who assumed the role in May, highlighted the company's essential role in healthcare and expressed confidence in the second half, citing stable demand and new capacity coming online.
Sotera Health CoRaises 2026 outlook after strong Q2 with revenue and EBITDA growth.